Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11103451 | 0.89 | CA2 (0.71) | CA2CA1CA12CA9DGAT1 | |
| SCHEMBL11103438 | 0.89 | CA2 (0.71) | CA2CA1CA12CA9DGAT1 | |
| SCHEMBL13761376 | 0.83 | MLYCD (0.58) | HDAC4ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL821456 | 0.81 | CA2 (0.63) | CA2CA1CA12CA9HDAC6 | |
| SCHEMBL1981446 | 0.81 | CA2 (0.63) | CA2CA1CA12CA9HDAC6 | |
| SCHEMBL12302109 | 0.81 | CA2 (0.63) | CA2CA1CA12CA9HDAC6 | |
| SCHEMBL698879 | 0.81 | CA1 (0.62) | CA2CA1CA12CA9DGAT1 | |
| SCHEMBL2796740 | 0.81 | CA1 (0.62) | CA2CA1CA12CA9DGAT1 | |
| SCHEMBL698880 | 0.81 | CA1 (0.62) | CA2CA1CA12CA9DGAT1 | |
| SCHEMBL3995339 | 0.80 | NPC1 (0.63) | CA2CA1CA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170258861-A1 | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | SQUIRES MERYL J (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258861-A1 | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | NISCH, CUTA, HRH1 | CA2 277/4885CA1 629/4885CA12 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.